An Esperion Therapeutics drug that pairs two cholesterol-lowering medicines in a single pill has been approved by the FDA, the second regulatory nod for the company in less than a week.
The reglator’s decision covers the combination of Esperion’s bempedoic acid (Nexletol) and ezetimibe, an older generic drug for reducing levels of the “bad” form of cholesterol. Last Friday, the agency approved bempedoic acid by itself. Following the Wednesday approval of the combination therapy, shares of Ann Arbor, MI-based Esperion (NASDAQ: ESPR) rose more than 2 percent to $58.30 apiece in after-hours trading.
Bempedoic acid, a once-daily pill, was… Read more »
UNDERWRITERS AND PARTNERS